GlaxoSmithKline (GSK), announced the company has appointed Dan Troy as senior vice president and general counsel and Dan will join the company on 2nd September 2008.

Dan was formerly chief counsel for the US Food and Drug Administration (FDA), where he served as a primary liaison to the White House and the US Department of Health and Human Services (HHS). While leading an office of attorneys who reviewed and approved all major regulations, Dan oversaw the legislative implications of many of the most important issues facing the pharmaceutical industry today, including the reform of the Hatch-Waxman Act and subsequent legislative ratification. His office also approved and managed all agency litigation, and Dan established new procedures for the FDA legal team to follow in preparing and then litigating high-profile cases.

Dan is currently a Partner at the Washington law firm Sidley Austin LLP, where he represents pharmaceutical companies and trade associations on matters related to the FDA and government regulations.

Andrew Witty, chief executive officer at GlaxoSmithKline, commented, "Dan shares our vision that it is critical in today's healthcare environment that we deliver differentiated products of real value to patients and payors. His wealth of experience in the regulatory legislative area will be of enormous benefit to us, and ultimately to patients. I am delighted that Dan will be joining GSK and look forward to welcoming him on to the corporate executive team."